echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Circulation: Statins for the prevention of cardiovascular disease, benefit more than 10 years!

    Circulation: Statins for the prevention of cardiovascular disease, benefit more than 10 years!

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cholesterol guidelines generally prioritize primary prevention statin therapy based on 10-year cardiovascular disease risk
    .


    The advent of generic drug prices may justify expanding eligibility for statins


    Cholesterol guidelines generally prioritize primary prevention statin therapy based on 10-year cardiovascular disease risk


    The researchers designed a computer simulation model to predict long-term health and cost outcomes in Scottish adults aged ≥40 years
    .


    Epidemiological analyses were completed using the Scottish Heart Health Expansion Cohort, Scottish Incidence Records, and Scottish National Records


    The primary outcome measure was the lifetime incremental cost-effectiveness ratio (ICER), estimated as the cost per quality-adjusted life-year (QALY) acquired
    .


    Three approaches to prioritizing statins were analyzed: 10-year risk score using ASSIGN score, age-stratified (Age-Strat) risk threshold to increase treatment rates in younger individuals, and absolute risk reduction (ARR) to guide treatment to Increase treatment rates in individuals with elevated cholesterol levels


    Results showed that the policy, compared with ASSIGN 20, lowered the risk threshold for statin initiation to 10%, expanding eligibility from 804,000 (32% of adults ≥40 years of age without cardiovascular disease) to 1,445,500 (58 %)
    .


    This policy will be cost effective (ICER: £12,300/QALY, 95% CI: £7,690/QALY - £26,500/QALY)


    This policy will be cost effective (ICER: £12,300/QALY, 95% CI: £7,690/QALY - £26,500/QALY)


    Furthermore, the delta of ARR 10 yielded around 7,950 QALYs compared to ASSIGN 10, which is cost-effective (£11,700/QALY, 95% CI: £9,250/QALY - £16,900/QALY)
    .


    Both age-stratified risk threshold strategies were dominant (ie, more expensive and less effective than other treatment strategies)


    Furthermore, the delta of ARR 10 yielded around 7,950 QALYs compared to ASSIGN 10, which is cost-effective (£11,700/QALY, 95% CI: £9,250/QALY - £16,900/QALY) Furthermore, compared to ASSIGN 10 , an increment of ARR 10 yielded about 7,950 QALYs, cost-effective (£11,700/QALY, 95% CI: £9,250/QALY - £16,900/QALY)

    Taken together, generic pricing makes prophylactic statin therapy cost-effective for many adults
    .


    Treatment guided by absolute risk reduction is more effective and cost-effective than the 10-year risk score


    Taken together, generic pricing makes prophylactic statin therapy cost-effective for many adults


    references:

    Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.